Skip to main content
Top
Published in: Current Hematologic Malignancy Reports 4/2022

26-05-2022 | Acute Lymphoblastic Leukemia | ACUTE LYMPHOCYTIC LEUKEMIA (R. MESA, SECTION EDITOR)

MRD in ALL: Optimization and Innovations

Authors: Eric Pierce, Benjamin Mautner, Joseph Mort, Anastassia Blewett, Amy Morris, Michael Keng, Firas El Chaer

Published in: Current Hematologic Malignancy Reports | Issue 4/2022

Login to get access

Abstract

Purpose of Review

Measurable residual disease (MRD) is an important monitoring parameter that can help predict survival outcomes in acute lymphoblastic leukemia (ALL). Identifying patients with MRD has the potential to decrease the risk of relapse with the initiation of early salvage therapy and to help guide decision making regarding allogeneic hematopoietic cell transplantation. In this review, we discuss MRD in ALL, focusing on advantages and limitations between MRD testing techniques and how to monitor MRD in specific patient populations.

Recent Findings

MRD has traditionally been measured through bone marrow samples, but more data for evaluation of MRD via peripheral blood is emerging. Current and developmental testing strategies for MRD include multiparametric flow cytometry (MFC), next-generation sequencing (NGS), quantitative polymerase chain reaction (qPCR), and ClonoSeq. Novel therapies are incorporating MRD as an outcome measure to demonstrate efficacy, including blinatumomab, inotuzumab ozogamicin, and chimeric antigen receptor T (CAR-T) cell therapy.

Summary

Understanding how to incorporate MRD testing into the management of ALL could improve patient outcomes and predict efficacy of new therapy options.
Literature
6.
go back to reference • Berry DA. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580. https://doi.org/10.1001/jamaoncol.2017.0580. This meta-analysis including 39 studies showed significantly improved event-free survival and overall survival for adult and pediatric patients with ALL who achieved MRD negativity following induction therapy.CrossRefPubMedPubMedCentral • Berry DA. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580. https://​doi.​org/​10.​1001/​jamaoncol.​2017.​0580. This meta-analysis including 39 studies showed significantly improved event-free survival and overall survival for adult and pediatric patients with ALL who achieved MRD negativity following induction therapy.CrossRefPubMedPubMedCentral
13.
go back to reference Foroni L. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis. Br J Haematol. 1999;105(1):7–24.PubMed Foroni L. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis. Br J Haematol. 1999;105(1):7–24.PubMed
15.
go back to reference Brisco J. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood. 1996;87(12):5251–6.CrossRef Brisco J. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood. 1996;87(12):5251–6.CrossRef
24.
go back to reference Ribera JM. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014;32(15):1595–604. https://doi.org/10.1200/JCO.2013.52.2425.CrossRefPubMed Ribera JM. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014;32(15):1595–604. https://​doi.​org/​10.​1200/​JCO.​2013.​52.​2425.CrossRefPubMed
40.
go back to reference • Shen Z. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis. BMC Cancer. 2018;18(1):755. https://doi.org/10.1186/s12885-018-4670-5. This meta-analysis including 21 studies showed patients with positive MRD prior to allogeneic stem cell transplantation was a significant negative predictor of relapse-free survival, event-free survival, and overall survival as compared to those with negative MRD.CrossRefPubMedPubMedCentral • Shen Z. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis. BMC Cancer. 2018;18(1):755. https://​doi.​org/​10.​1186/​s12885-018-4670-5. This meta-analysis including 21 studies showed patients with positive MRD prior to allogeneic stem cell transplantation was a significant negative predictor of relapse-free survival, event-free survival, and overall survival as compared to those with negative MRD.CrossRefPubMedPubMedCentral
42.
go back to reference • Li S. Different effects of pre-transplantation measurable residual disease on outcomes according to transplant modality in patients with Philadelphia chromosome positive ALL. Front Oncol. 2020;10:320. https://doi.org/10.3389/fonc.2020.00320. This retrospective study evaluated the effects of MRD positivity prior to allogeneic HCT for management of Philadelphia chromosome positive ALL and revealed that haploidentical HCT was related to higher probability of survival and lower incidences of relapse as compared to matched sibling donor HCT in this patient population.CrossRefPubMedPubMedCentral • Li S. Different effects of pre-transplantation measurable residual disease on outcomes according to transplant modality in patients with Philadelphia chromosome positive ALL. Front Oncol. 2020;10:320. https://​doi.​org/​10.​3389/​fonc.​2020.​00320. This retrospective study evaluated the effects of MRD positivity prior to allogeneic HCT for management of Philadelphia chromosome positive ALL and revealed that haploidentical HCT was related to higher probability of survival and lower incidences of relapse as compared to matched sibling donor HCT in this patient population.CrossRefPubMedPubMedCentral
43.
49.
go back to reference Akahoshi Y. Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT. Bone Marrow Transplant. 2020;55(7):1317–25. https://doi.org/10.1038/s41409-020-0951-0.CrossRefPubMed Akahoshi Y. Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT. Bone Marrow Transplant. 2020;55(7):1317–25. https://​doi.​org/​10.​1038/​s41409-020-0951-0.CrossRefPubMed
54.
go back to reference Miyamura K. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation. Blood. 1992;79(5):1366–70.CrossRef Miyamura K. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation. Blood. 1992;79(5):1366–70.CrossRef
55.
go back to reference Radich J. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood. 1997;89(7):2602–9.CrossRef Radich J. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood. 1997;89(7):2602–9.CrossRef
58.
go back to reference Candoni A. Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors: a registry-based study of the Italian Blood and Marrow Transplantation Society (GITMO). Biol Blood Marrow Transplant. 2019;25(12):2388–97. https://doi.org/10.1016/j.bbmt.2019.07.037.CrossRefPubMed Candoni A. Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors: a registry-based study of the Italian Blood and Marrow Transplantation Society (GITMO). Biol Blood Marrow Transplant. 2019;25(12):2388–97. https://​doi.​org/​10.​1016/​j.​bbmt.​2019.​07.​037.CrossRefPubMed
61.
go back to reference Löffler A. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95(6):2098–103.CrossRef Löffler A. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95(6):2098–103.CrossRef
63.
go back to reference Martinelli G. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35(16):1795–802. https://doi.org/10.1200/JCO.2016.69.3531.CrossRefPubMed Martinelli G. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35(16):1795–802. https://​doi.​org/​10.​1200/​JCO.​2016.​69.​3531.CrossRefPubMed
67.
go back to reference • Gökbuget N. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522–31. https://doi.org/10.1182/blood-2017-08-798322. This prospective, single-arm, phase II study showed that a majority of patients in hematologic remission with MRD positivity after chemotherapy achieved a complete MRD response to blinatumomab and a significant OS improvement in MRD responders.CrossRefPubMedPubMedCentral • Gökbuget N. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522–31. https://​doi.​org/​10.​1182/​blood-2017-08-798322. This prospective, single-arm, phase II study showed that a majority of patients in hematologic remission with MRD positivity after chemotherapy achieved a complete MRD response to blinatumomab and a significant OS improvement in MRD responders.CrossRefPubMedPubMedCentral
94.
go back to reference Flohr T. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22(4):771–82. https://doi.org/10.1038/leu.2008.5.CrossRefPubMed Flohr T. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22(4):771–82. https://​doi.​org/​10.​1038/​leu.​2008.​5.CrossRefPubMed
100.
go back to reference • Kotrova M. Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia. Leukemia. 2020;34(4):1154–7. https://doi.org/10.1038/s41375-019-0599-1. This retrospective study evaluated bone marrow and peripheral blood sample pairs from B-ALL and T-ALL patients using EuroMRD allele-specific oligonucleotide RQ-PCR and EuroMRD guidelines and revealed stronger correlation of MRD in bone marrow and peripheral blood in T-cell ALL when compared to B-cell ALL.CrossRefPubMed • Kotrova M. Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia. Leukemia. 2020;34(4):1154–7. https://​doi.​org/​10.​1038/​s41375-019-0599-1. This retrospective study evaluated bone marrow and peripheral blood sample pairs from B-ALL and T-ALL patients using EuroMRD allele-specific oligonucleotide RQ-PCR and EuroMRD guidelines and revealed stronger correlation of MRD in bone marrow and peripheral blood in T-cell ALL when compared to B-cell ALL.CrossRefPubMed
Metadata
Title
MRD in ALL: Optimization and Innovations
Authors
Eric Pierce
Benjamin Mautner
Joseph Mort
Anastassia Blewett
Amy Morris
Michael Keng
Firas El Chaer
Publication date
26-05-2022
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 4/2022
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-022-00664-6